TLX News: First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent - 14th Apr 2022, 9:00pm

[annb0t]

Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent

Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cancer[1]

INDIANAPOLIS, April 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first commercial doses of its prostate cancer imaging agent, Illucc...

>>> Read more: First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent